3.4.22.27: cathepsin S
This is an abbreviated version!
For detailed information about cathepsin S, go to the full flat file.
Word Map on EC 3.4.22.27
-
3.4.22.27
-
cathepsins
-
lysosomal
-
point-of-care
-
cystatins
-
dendritic
-
atherosclerosis
-
proteinases
-
elastin
-
papain
-
antigen-presenting
-
histocompatibility
-
autoimmune
-
drug development
-
lacrimal
-
papain-like
-
diagnostics
-
ii-associated
-
elastolytic
-
resource-limited
-
s-deficient
-
procathepsins
-
l-like
-
pharmacology
-
endostatin
-
microglial
-
fractalkine
-
medicine
-
par2
-
collagenolytic
-
syphilis
-
ii-restricted
- 3.4.22.27
- cathepsins
- lysosomal
-
point-of-care
- cystatins
- dendritic
- atherosclerosis
- proteinases
- elastin
- papain
-
antigen-presenting
-
histocompatibility
- autoimmune
- drug development
-
lacrimal
-
papain-like
- diagnostics
-
ii-associated
-
elastolytic
-
resource-limited
-
s-deficient
-
procathepsins
-
l-like
- pharmacology
- endostatin
- microglial
- fractalkine
- medicine
- par2
-
collagenolytic
- syphilis
-
ii-restricted
Reaction
similar to cathepsin L, but with much less activity on Z-Phe-Arg-/-NHMec, and additional information activity on the Z-Val-Val-Arg-/- compound =
Synonyms
C01.034, Cat S, Cat-S, cath S, cathepsin S, cathepsin S-like cysteine proteinase, cathepsin Sa, CatS, CatSPP, CTSS, Hacp-s, PfCTSSa, PoCtS, rs1136774, rs16827671, rs34495036, rs35989725, rs3754212, rs7534124, SoCatS
ECTree
3.4.22.27 cathepsin SAdvanced search results
results (
results (Application
Application on EC 3.4.22.27 - cathepsin S
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
top
APPLICATION 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
diagnostics
drug development
medicine
pharmacology
-
the enzyme might be a good target for development of inhibitors in treatment of collagen-induced arthritis and autoimmune myasthenia gravis
diagnostics
-
an increased serum level of cathepsin S may serve as a biomarker for atherosclerosis and diabetes
diagnostics
-
cathepsin S is a biomarker for adiposity and has relevance to atherogenesis
drug development
brain-penetrating cathepsin S inhibitors demonstrate potential clinical utility for the treatment of multiple sclerosis and neuropathic pain
drug development
Cat S is an attractive therapeutic target and selective Cat S inhibitors may also modulate a number of other diseases such as rheumatoid arthritis, multiple sclerosis, myasthenia gravis, asthma, atherosclerosis and neuropathic pain
drug development
-
cat S is an attractive therapeutic target for the treatment of autoimmune disorders
drug development
-
CatS is involved in the pathogenesis of autoimmune disorders, atherosclerosis and obesity, therefore, it represents a promising pharmacological target for drug development
drug development
-
discovery of orally bioavailable cathepsin S inhibitors for the reversal of neuropathic pain, cathepsin S inhibitors are attractive targets as immunological therapeutic agents
drug development
-
discovery of orally bioavailable cathepsin S inhibitors for the reversal of neuropathic pain, cathepsin S inhibitors are attractive targets as immunological therapeutic agents
drug development
discovery of orally bioavailable cathepsin S inhibitors for the reversal of neuropathic pain, cathepsin S inhibitors are attractive targets as immunological therapeutic agents
drug development
-
enzyme may be a potential target in rheumatoid arthritis and obesity with its associated cardiovascular risks
drug development
-
importance of CATS in inflammatory processes, which has generated much interest in the development of CATS inhibitors as immunomodulatory therapeutics for immune disorders such as bronchial asthma, rheumatoid arthritis and psoriasis, CATS may also be an attractive target in neurodegenerative disorders associated with inflammation
drug development
-
important role for cathepsin S in the regulation of ozone-induced airway hyperresponsiveness and neutrophil cell recruitment, cathepsin S may be a target in the treatment of oxidative stress-induced airway hyperresponsiveness and inflammation
drug development
-
increased risk of mortality and morbidity associates with cardiovascular calcification drives the development of new therapeutic strategies to prevent and potentially reverse this process, new therapeutic options may also include selective inhibition of catS
drug development
-
inhibition of the proteolytic activity of cathepsin S is an attractive target for drug development with such inhibitors having potential for modulation and regulation of autoimmune diseases such as multiple sclerosis and rheumatoid arthritis, and allergic disorders, such as asthma
medicine
-
cathepsin S is a potential therapeutic target for regulation of major histocompatibility complex class II immune responses, possibly resulting in treatments for autoimmune diseases and allergic asthma
medicine
-
cathepsin S is a potential therapeutic target for regulation of major histocompatibility complex class II immune responses, possibly resulting in treatments for autoimmune diseases and allergic asthma
medicine
-
cathepsin S is a potential therapeutic target for regulation of major histocompatibility complex class II immune responses, possibly resulting in treatments for autoimmune diseases and allergic asthma
medicine
-
the inhibitor JNJ 10329670 is a candidate for immunosuppressive therapy of allergies and autoimmune diseases, completely reversible inhibition
medicine
tear cathepsin S serves as a candidate biomarker for Sjögren's Syndrome
medicine
Cat-S or PAR2 inhibition might be a strategy to prevent microvascular disease in diabetes and other diseases
medicine
cathepsin S activation of PAR-2 may represent a potential therapeutic target for amelioration of ocular surface inflammation in Sjögren's syndrome patients
